KRAS and non-small cell lung carcinoma: When we compared gene and pathway alterations seen in the BM specimens, stratified by histology (LUAD, squamous cell carcinoma [SCC], and other NSCLC) we noted more frequent KRAS and STK11 alterations (KRAS: 35% vs 9%, p = 0.